Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 19 unusual trades.
Delving into the details, we found 26% of traders were bullish, while 63% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $762,532, and 5 were calls, valued at $755,304.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $290.0 to $340.0 for Amgen over the last 3 months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $290.0 to $340.0 over the preceding 30 days.
Amgen Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BEARISH | 06/20/25 | $4.55 | $4.25 | $4.25 | $340.00 | $413.1K | 449 | 977 |
| AMGN | CALL | TRADE | BEARISH | 04/17/25 | $4.2 | $3.8 | $3.8 | $312.50 | $229.1K | 3 | 605 |
| AMGN | PUT | SWEEP | BEARISH | 05/16/25 | $10.6 | $10.25 | $10.6 | $305.00 | $72.0K | 735 | 19 |
| AMGN | PUT | TRADE | NEUTRAL | 04/04/25 | $1.81 | $1.6 | $1.7 | $300.00 | $71.7K | 52 | 926 |
| AMGN | PUT | TRADE | NEUTRAL | 04/04/25 | $1.71 | $1.44 | $1.6 | $300.00 | $67.5K | 52 | 504 |
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
Present Market Standing of Amgen
- Trading volume stands at 1,441,651, with AMGN's price down by -3.31%, positioned at $303.98.
- RSI indicators show the stock to be may be approaching oversold.
- Earnings announcement expected in 37 days.
Expert Opinions on Amgen
1 market experts have recently issued ratings for this stock, with a consensus target price of $294.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from B of A Securities persists with their Underperform rating on Amgen, maintaining a target price of $294.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, Benzinga Pro gives you real-time options trades alerts.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
